CERo Therapeutics enters new common stock purchase agreement for up to $17.5M with Keystone Capital

CERO THERAPEUTICS HOLDINGS, INC.

New Purchase Agreement allows CERo to issue and sell up to $17,490,897 of common stock to Keystone Capital, minus any additional proceeds from prior November deal after June 30, 2025.
Fixed purchases per notice capped at lower of 10,000 shares or $100,000; VWAP purchases aggregate limit of $10M.
Beneficial ownership limitation of 4.99% per purchase.
Registration Rights Agreement filed concurrently for shares issued.
Replaces prior equity lines from Feb '24 and Nov '24 which had raised ~$7.5M combined.

item 1.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.